Rights-protecting investors push for CEO removal; Pasirala Biological Sciences stock rises 2%

LootboxPhobia · 2026-03-11T17:55:37+00:00

Passira Biological Sciences stock price rose by 2%, activist investor DOMA Perpetual nominated three directors and called for the removal of CEO Li due to poor financial performance. The investor pointed out the company's long-term stock decline and criticized excessive executive compensation and the headquarters relocation issue.

LootboxPhobia

2026-03-11 17:55:37

Abstract generation in progress

Investing.com – Pacira BioSciences (NASDAQ:PCRX) stock rose 2% pre-market on Wednesday, reaching $22.78.

Shareholder activist DOMA Perpetual nominated three directors to the company’s board and called for the removal of CEO Frank Lee, citing poor financial performance over the years.

DOMA Perpetual stated that Pacira BioSciences’ stock has declined 56% over the past 10 years, 68% over the past 5 years, and 30% during Lee’s tenure as CEO.

The activist investor said that Pacira BioSciences is too small to effectively promote its non-opioid surgical pain relief drug Exparel and urged the company to initiate a formal sale process.

DOMA Perpetual also criticized the company’s board for approving high executive compensation and relocating the headquarters to San Francisco.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.